Categories
Uncategorized

Sanofi, GlaxoSmithKline set to start Phase 3 trials for COVID-19 vaccine after earlier setback

Sanofi Toronto

A COVID-19 vaccine developed by Sanofi and GlaxoSmithKline showed a robust immune response in early-stage clinical trial results, enabling them to move to a late-stage study, the companies announced on Monday.

Leave a Reply

Your email address will not be published. Required fields are marked *